BrainStorm receives FDA clearance to initiate Phase 3b trial of NurOwn for ALS

BRAINSTORM CELL THERAPEUTICS INC.

FDA cleared Phase 3b trial under Special Protocol Assessment (SPA); endpoints agreed for future BLA.
Trial to enroll ~200 participants at academic centers; 24-week double-blind phase plus 24-week open-label extension.
Primary endpoint: change from baseline to week 24 on ALS Functional Rating Scale-Revised (ALSFRS-R).
Company plans to activate sites in phases and secure funding via non-dilutive grants.
Investor call and webcast scheduled for May 19 at 8:30 a.m. ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.